Comparing treatments for rheumatoid arthritis with lung disease
Treatments studied
Part of Bones, joints & muscles, Lungs & breathing clinical trials.
This study compares different treatment strategies for people with rheumatoid arthritis who also have interstitial lung disease (a type of lung scarring). It aims to find the best way to manage both conditions and potentially slow lung damage.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have rheumatoid arthritis, diagnosed by standard criteria.
- A CT scan of your chest shows lung scarring (interstitial lung disease) covering at least 20% of your lungs.
- Your lung function tests show reduced capacity (FVC below 80% or DLCO below 70% of predicted).
- If you take steroids, you must be on a stable low dose (10 mg or less of prednisone daily) for at least 4 weeks.
- If you take other arthritis medications (csDMARDs), your dose must be stable for at least 4 weeks.
- You must not have other autoimmune diseases, active infections, or recent cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study combines traditional Chinese medicine with Western medicine to treat rheumatoid arthritis. It aims to see how well this approach works for people with hard-to-treat RA or RA-related lung disease.
This trial is for people with rheumatoid arthritis (RA) who are at risk for developing interstitial lung disease, which is scarring in the lungs. It aims to better understand why this happens and how to help prevent or manage it.
This study is looking at people with rheumatoid arthritis (RA) who also have interstitial lung disease (ILD), a condition that causes scarring in the lungs. It aims to understand how the disease changes over time by using imaging and blood tests, without providing any new treatments right now.
This study helps doctors identify early signs of lung scarring (fibrosis) in patients with autoimmune diseases like scleroderma, rheumatoid arthritis, and Sjögren's syndrome. By catching this early, researchers hope to better understand and treat these complications.
This trial studies lung scans (HRCT) from patients with rheumatoid arthritis, interstitial lung disease, or connective tissue disease to better understand lung involvement. If you have one of these conditions and have had a lung CT, you may be able to help.
This trial tests whether combining two drugs, rituximab and mycophenolate mofetil, is safe and works better than standard care for lung scarring caused by scleroderma. It may be an option if your lung disease is severe or getting worse.
Hear when a new Rheumatoid Arthritis-Associated Interstitial Lung Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.